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Surveillance guidelines for the management of familial colorectal cancer (FCC), a dominant family history of colorectal cancer
in which the polyposis syndromes and Lynch syndrome have been excluded, are not firmly established. The outcome of colo-
noscopic surveillance is studied using data from six centers. DNA mismatch repair deficiency was excluded by genetic testing.
Families were classified as FCC type X if they fulfilled the original Amsterdam criteria (AC) and late onset (LOFCC) if they ful-
filled the AC apart from not having a cancer aged under 50. The most advanced findings on colonoscopy were analyzed. One
thousand five hundred eighty-five individuals (median age 47.3, 44% male) from 530 FCC families (349 FCC type X) underwent
a total of 4,992 colonoscopies with 7,904 patient-years of follow-up. Results for FCC type X and LOFCC were very similar. At
baseline, 22 prevalent asymptomatic colorectal cancers were diagnosed, 120 (7.6%) individuals had high-risk adenomas and
225 (14.2%) simple adenomas. One thousand eighty-eight individuals had a further colonoscopy (median follow-up of 6.2
years). Of nine individuals diagnosed with cancer, eight had a previous history of at least one polyp/adenoma. High-risk
adenomas were detected in 92 (8.7%) and multiple adenomas were detected in 20 (1.9%) individuals. Both FCC type X and
LOFCC have a high prevalence of colorectal cancers and on follow-up develop high-risk adenomas (including multiple adeno-
mas), but infrequent interval cancers. They should be managed similarly with five-yearly colonoscopies undertaken from
between 30 and 40 with more intensive surveillance in individuals developing multiple or high-risk adenomas.
Approximately, 3–5% of all cases of colorectal cancer (CRC)
are associated with a highly-penetrant, dominantly inherited
syndrome. These syndromes may be identified due to a
strong family history of CRC and, by their phenotype or by
germline genetic testing, and their clinical management is
firmly established.1,2 The most common syndrome is Lynch
syndrome (LS) (previously known as hereditary nonpolyposis
colorectal cancer—HNPCC). LS is caused by an inherited
alteration of DNA mismatch repair genes (MLH1, MSH2,
MSH6 or PMS2), which results in DNA microsatellite insta-
bility (MSI) in the tumor. Familial adenomatous polyposis
and the hamartomatous syndromes are rarer. Familial
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colorectal cancer (FCC) refers to the larger number of fami-
lies who have dominantly inherited CRC but no polyposis
phenotype and no evidence of altered DNA mismatch repair
genes. Families who fulfill the three Amsterdam Criteria I for
HNPCC [(i) At least three relatives over two generations
affected with a CRC one of whom is a first-degree relative of
the other two, (ii) FAP excluded, (iii) one CRC diagnosed
aged under 502], are referred to as FCC type X, and families
who fulfill the criteria, except that they have no relatives
diagnosed with CRC under the age of 50 years, are referred
to as Late Onset FCC (LOFCC).
Lindor et al. have investigated the phenotype of FCC type
X families and have shown that there is no increased inci-
dence of the extra-colonic cancers (endometrial, ovarian,
stomach, brain and small intestine) associated with LS and
that the risk of CRC appears to be less than in LS.3 Authors
of this study have previously undertaken studies on the out-
come of colonoscopic surveillance in FCC type X families.4–7
Nevertheless, there is still a paucity of prospective evidence
as to how the risk of CRC should be managed in FCC. The
aim of this study was to use data pooled from six European
centers to evaluate the outcome of prospective colonoscopic
surveillance of individuals from FCC families to see whether
recommendations for surveillance could be made based on
the results. The protocols for surveillance vary between the
centers and thus provide some information on the relative
benefit of different age at initial surveillance and different
intervals between surveillance colonoscopies.
Material and Methods
We approached European centers that have prospectively col-
lected colonoscopic surveillance data from individuals from
families at a high risk of CRC. The data presented are from
six centers; Central Manchester University Hospitals NHS
Foundation Trust, Manchester, UK; German Consortium for
Hereditary Non-Polyposis Colorectal Cancer, Germany; The
Danish HNPCC-register, Copenhagen University Hospital,
Hvidovre, Denmark; Karolinska University Hospital, Stock-
holm, Sweden; The Netherlands Foundation for the Detection
of Hereditary Tumours, Leiden, The Netherlands and St
Mark’s Hospital, London, UK.
Data were collected for individuals from FCC families.
Patients eligible for the study were the first-degree, at-risk
relatives of the defining CRC triad undergoing colonoscopic
surveillance. The group was divided into FCC type X and
LOFCC. Individuals from families with known germline LS
mutations were not eligible.
DNA mismatch repair deficiency was excluded in the fam-
ilies by one of two methods in each of the centers and fami-
lies were defined into two groups:
 Tumor testing group: One or more CRC tumors tested
within each pedigree of which >50% tumors are microsa-
tellite stable (MSS) (Bat 26 sufficient) and/or do not dem-
onstrate loss of expression of the DNA mismatch repair
genes (MLH1, MSH2, MSH6 or PMS2) using
immunohistochemistry.
 Germline testing group: families in whom only germline
sequencing of at least the DNA mismatch repair genes
MLH1 and MSH2 has been undertaken and no mutations
detected.
For all eligible patients, data were collected on: (i) family
history (Amsterdam Criteria I/family history, details of any
metachronous and/or synchronous colorectal lesions in any
defining triad member, details of any individual with a cancer
(colorectal and extra colonic) found within the family includ-
ing their sex, age, DNA MSI testing, date of birth, date of
death, site of cancer, stage of cancer); (ii) patients undergoing
colonoscopy (age, sex, date of birth, date of death); (iii) colo-
noscopy details for each colonoscopy performed (date, result,
details of any tissue removed including histology, site, size,
hyperplastic polyp, adenoma (tubular or villous), grade of
dysplasia and whether colonoscopy was complete to cecum).
Pseudonymized data from each center were sent retro-
spectively to DM and data were reformatted and pooled to a
single secure database. Data sent and details of each center
are shown in Table 1.
The baseline colonoscopy was defined as the first colono-
scopy undertaken in an individual. All subsequent colonos-
copies are considered to be in the follow-up period of
surveillance. We identified all cancers found at the baseline
colonoscopy (or due to immediate follow-up of an abnormal
baseline colonoscopy). If the baseline colonoscopy was per-
formed due to symptoms, cancers were considered to be
symptomatic and excluded from both the baseline analysis
and any follow-up analysis. Otherwise, any cancer detected
was considered to be “(asymptomatic), prevalent screen
detected” and the results of further surveillance for these
individuals were excluded from the follow-up analysis.
The endpoints of the study are presence of adenomas or
cancer. Multiple adenomas were defined as an occurrence of
three or more adenomas on any one colonoscopy, five or
more adenomas by the age of 50 years, eight or more by age
60, 11 or more by age 70 or 14 or more adenomas over total
What’s new?
About 3-5 percent of colorectal cancer cases are associated with a highly penetrant dominant inherited syndrome. However,
established guidelines for the surveillance of Familial Colorectal Cancer (FCC), in which the Polyposis syndromes and Lynch
syndrome have been excluded, are lacking. This study suggests that FCC and late-onset FCC (LOFCC) patients should be man-
aged with five-yearly colonoscopies between ages 30 and 40, with more intensive surveillance in individuals who develop
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surveillance period. High-risk adenomas were defined as an
adenoma with villous histology or a diameter > 10 mm or
high-grade dysplasia.
The pooled analysis of pseudonymized data is considered
to be service evaluation and did not require ethical approval
in the UK. Ethical approval was obtained locally, where
required, for the original data collection.
Statistical methods
Total surveillance period is taken from the time of the base-
line colonoscopy to the last colonoscopy (excluding those
after the diagnosis of CRC) for each individual under
surveillance.
We initially report the most advanced finding on the base-
line colonoscopy for each individual (Normal, Hyperplastic
polyp(s), Adenoma(s), High-risk adenoma, CRC). This result
is tabulated against familial phenotype. Percentages are
weighted to standardize by age group to allow for differences
in the age at first screen between individuals from FCC type
X and LOFCC families.
Using published data from the Flexi-sig trial,8 we estimated
the number of distal cancers detected soon after randomiza-
tion in the screened arm to be approximately equal to the
number of distal cancers diagnosed within 4.0 years of ran-
domization in the control arm. Assuming the lead-time distri-
bution and sensitivity of endoscopy in this study was similar
to that in the Flexi-sig trial, the number of CRCs found in the
baseline colonoscopy here would be similar to the number
expected over 4 years in the absence of screening. Had our
cohort had average population risk, the “expected” number of
incident cancers in the four years following baseline colono-
scopy was calculated using CRC rates from England for 2009
stratified by sex and 5-year age group.9
The most advanced pathological finding on any subse-
quent colonoscopy is presented according to the baseline
colonoscopy result.
Rates of (first) adenoma, high-risk adenoma and CRC
(dependent on age, sex, familial phenotype and previous find-
ings) are calculated with individuals censored at the first
event (as this may prevent the subsequent development of
high-risk adenomas or cancers). Events found at a colono-
scopy are assumed to have developed between the previous
colonoscopy and the diagnosing colonoscopy.
In order to estimate the cumulative proportion of subjects
at different ages with a particular event (adenoma/multiple
adenomas/high-risk adenoma/CRC), we consider the time to
first event in an individual. For each individual and each
event type, we consider the last colonoscopy before an event
was found and the first colonoscopy on which an event was
found. The data are interval censored as the date of an event
is only known to be at some point since an individual’s pre-
vious colonoscopy. For individuals without an event, we con-
sider only their last colonoscopy. Similarly, only the first is
used for an individual with an event found at baseline. As
event times are either left-censored or right censored (never
observed exactly), the Kaplan–Meier estimates are not appro-
priate, hence the proportion of colonoscopies with an event
is estimated by smoothing (we used the Stata command low-
ess which is similar to a moving average) and the result is
forced to be non-decreasing in age by applying the pool adja-
cent violators algorithm.10
Results
The outcome of colonoscopic surveillance was collected for
1,585 at-risk individuals from 530 FCC families from the six
European centers. A total of 4,992 colonoscopies have been
undertaken with 7,904 person-years of follow-up.
DNA mismatch repair deficiency was excluded by testing
one or more cancer for MSI and/or immunohistochemistry
in 81.5% of families and by germline genetic testing of
MLH1 and MSH2 alone in 18.5% of families. The method
used varied between centers between 66% and 100% of fami-
lies classified by tumor testing at each center. The median
number of colonoscopies per individual ranged from 2 to 4
across centers and median total follow-up ranged from 2.2
years to 8.7 years. Age at baseline colonoscopy and the pro-
portion of males was similar across centers with median val-
ues of 47.5 years and 44%, respectively. Full details are
shown in Table 2.
Of 1,585 individuals under surveillance, 1,126 (71%) were
from families classified as FCC type X and 459 (29%) from
LOFCC with a total of 3,790 and 1,202 surveillance colonos-
copies, respectively. Median follow-up was slightly higher
amongst individuals from FCC type X families compared to
LOFCC (median (range) follow-up time: 4.1 years (0, 30.6)
and 3.0 years (0, 34.9) respectively).
Findings at baseline colonoscopy
In total, there were 44 (2.8%) cancers that were identified
either at the baseline screen or on further investigation of an
abnormality detected at baseline colonoscopy. The age at can-
cer diagnosis ranged from 31 to 79 years (median age 51.5
years). Twenty-two cancers were diagnosed in individuals
who were symptomatic (e.g., change in bowel habit, rectal
bleeding or anemia) at the time that they were referred for
colonoscopy and these cases were excluded from analysis. In
the remaining 22 individuals, cancers were classified as
asymptomatic prevalent cancers. Based on data of CRC diag-
noses in England in 2009,9 we calculated an expected number
of prevalent cancers on the baseline colonoscopy of 4.08. Rel-
ative to this, the 22 asymptomatic prevalent cancers yield a
(standardized prevalence) ratio of 5.4 (95% CI 3.4–8.2) com-
pared to the general population. Of the 44 cancers, 32 were
from the left side of the colon and 11 from the right (there
were slightly more cancers from the left side of the colon
amongst those with symptoms than those who were asymp-
tomatic: 86% vs. 64%, respectively).
At least one adenoma was reported in 345/1,585 (21.8%)
individuals and, of these, 120/345 (34.8%) were categorized
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individuals from type X families was slightly younger than
those from LOFCC families (51 years vs. 54 years). Adjusting
for age, the results were similar for those families classified
by tumor and by germline genetic testing. There was a
slightly higher proportion of normal colonoscopy in individu-
als from FCC type X than LOFCC families (66.8% vs. 57.6%
respectively, p< 0.0001) (Table 3).
Findings at follow-up surveillance colonoscopy
Of the 1,541 individuals who were not diagnosed with CRC
at baseline colonoscopy, 1,088 (70.6%) had at least one fur-
ther colonoscopy of whom 1,053 (96.8%) had at least one
result recorded. The worst (most advanced pathology) result
on follow-up relative to the baseline colonoscopy result is
shown in Tables (4–6). It is seen that the results for FCC
type X and LOFCC are similar (Tables 4 and 5). In the
cohort as a whole (Table 6) over a third of individuals with
either a high-risk adenoma or multiple adenomas at baseline
had a high-risk adenoma or cancer on follow-up. If we con-
sidered a more established definition of multiple adenomas
(i.e., three or more adenomas on any one colonoscopy or five
or more adenomas throughout the colonoscopic surveillance)
Table 3. Worst result at baseline for each individual (by subgroup). Numbers shown are n (age standardized percentage)
Subgroup
Worst result FCC type X Late onset FCC Total
Normal 760 (66.8) 256 (57.6) 1016 (64.1)
No histology recorded 28 (2.5) 10 (2.1) 38 (2.4)
Metaplastic/Hyperplastic Polyp 96 (8.5) 68 (14.7) 164 (10.3)
Adenoma(s) 151 (13.9) 74 (15.3) 225 (14.2)
High risk Adenoma1 75 (6.9) 45 (9.3) 120 (7.6)
Colorectal cancer 16 (1.5) 6 (1.1) 22 (1.4)
Total 1126 (100) 459 (100) 1585 (100)
1High Risk Adenoma is defined as an adenoma with villous histology or a diameter of 10 mm or greater or high-grade dysplasia.
Table 4. Initial result vs. worst colonoscopic result after initial colonoscopy amongst FCC type X families
Worst follow-up result







Normal 326 (63.8) 54 (10.6) 91 (17.8) 6 (1.2) 32 (6.3) 2 (0.4) 511 (100)
Hyperplastic Polyp 19 (25.3) 25 (33.3) 14 (18.7) 7 (9.3) 9 (12.0) 1 (1.3) 75 (100)
Adenoma 38 (36.5) 10 (9.6) 36 (34.6) 7 (6.7) 12 (11.5) 1 (1.0) 104 (100)
Multiple adenomas 3 (18.8) 2 (12.5) 1 (6.3) 2 (12.5) 6 (37.5) 2 (12.5) 16 (100)
High risk adenoma 24 (40.7) 2 (3.4) 11 (18.6) 1 (1.7) 21 (35.6) – 59 (100)
Total 410 (53.6) 93 (12.2) 153 (20.0) 23 (3.0) 80 (10.5) 6 (0.8) 765 (100)
Table 5. Initial result vs. worst colonoscopic result after initial colonoscopy amongst late onset FCC families
Worst follow-up result







Normal 100 (64.9) 17 (11.0) 26 (16.9) 4 (2.6) 7 (4.5) – 154 (100)
Hyperplastic Polyp 17 (40.5) 11 (26.2) 8 (19.0) – 5 (11.9) 1 (2.4) 42 (100)
Adenoma 22 (40.0) 9 (16.4) 17 (30.9) 1 (1.8) 6 (10.9) – 55 (100)
Multiple adenomas 1 (25.0) – 1 (25.0) – 1 (25.0) 1 (25.0) 4 (100)
High risk adenoma 11 (33.3) 3 (9.1) 5 (15.2) 2 (6.1) 11 (33.3) 1 (3.0) 33 (100)
Total 151 (52.4) 40 (13.9) 57 (19.8) 7 (2.4) 30 (10.4) 3 (1.0) 288 (100)








Mesher et al. 943
Int. J. Cancer: 134, 939–947 (2014) VC 2013 UICC
then there were 14 more individuals defined as having multi-
ple adenomas. None of these individuals went on to subse-
quently develop a high-risk adenoma or cancer. The lowest
risk of advanced neoplasia on surveillance was in those with
a normal baseline examination (6% had a high-risk adenoma
or worse). The risk of a subsequent high-risk adenoma or
worse was similar in those with a hyperplastic polyp (13.7%)
or an adenoma (11.9%) on baseline.
The cumulative proportions of individuals with increasing
age having a pathological finding on colonoscopy are shown
in Figure 1. Some adenomas are detected on initial colono-
scopy (from approximately age 25 years) with a steady
increase to just over 30% of individuals affected at 40 years
of age. The incidence of multiple adenomas and high-risk
adenomas increases after 40 years of age to 80 years of age
from approximately 10% to just over 20%.
A total of 1,513 adenomas were identified from all indi-
viduals included in the study. Of these, 390 (26%) were clas-
sified as high-risk adenomas. The risk of having a high-risk
adenoma was higher in individuals with a history of multiple
adenomas compared to those who had adenomas that were
not classified as multiple (53% and 33% respectively); how-
ever the proportion of adenomas which were classified as
high-risk was slightly lower in the multiple adenoma group
(21% vs. 29%). Data were collected on the distribution of
adenomas from Denmark, The Netherlands, Manchester,
Stockholm and London. From these five centers, a total of
465 adenomas were identified at the baseline colonoscopy.
Eleven adenomas (2.4%) were from an unknown location. Of
the remaining 454 adenomas, 248 (55%) were from the left
side, 183 (40%) from the right side and 23 (5.1%) were iden-
tified along with other adenomas on the same colonoscopy
and records showed adenomas from left and right side of the
colon. Throughout the total follow-up, 811 adenomas were
identified (31 unknown location); 352 (45%) from the left
side, 366 (47%) from the right side and 62 (7.9%) from both
the left and right side.
To determine whether the multiple adenoma phenotype
clustered within FCC families, the presence or absence of
multiple adenomas was assessed within families with at least
two members undergoing surveillance. In 55/999 (5.5%) of
individuals, only one family member had multiple adenomas.
In 23/347 (6.6%) of cases, multiple adenomas were also seen
in another family member giving a relative risk of 1.2 (95%
CI 0.8–1.6).
The proportion of individuals under surveillance develop-
ing CRC remains low across all ages. In total, nine CRCs
were identified during surveillance. Details of these cancers
are shown in Table 7. The time interval since the previous
colonoscopy ranged from 2 to 6 years, (median 2.7 years).
The ages of individuals at the time of their cancer diagnosis
ranged from 42 to 77 years.
Discussion
The results of a pooled multicenter comparative study of the
outcome of prospective colonoscopic surveillance in FCC
have been presented. Data have been collected for up to
more than 30 years and demonstrate that there is a high
prevalence of adenomas and CRC in the population studied,
the incidence of adenomas and advanced neoplasia is
increased compared to the general population, and that
Table 6. Initial result vs. worst colonoscopic result after initial colonoscopy amongst all families
Worst follow-up result







Normal 426 (64.1) 71 (10.7) 117 (17.6) 10 (1.5) 39 (5.9) 2 (0.3) 665 (100)
Hyperplastic Polyp 36 (30.8) 36 (30.8) 22 (18.8) 7 (6.0) 14 (12.0) 2 (1.7) 117 (100)
Adenoma 60 (37.7) 19 (12.0) 53 (33.3) 8 (5.0) 18 (11.3) 1 (0.6) 159 (100)
Multiple adenomas 4 (20.0) 2 (10.0) 2 (10.0) 2 (10.0) 7 (35.0) 3 (15.0) 20 (100)
High risk adenoma 35 (38.0) 5 (5.4) 16 (17.4) 3 (3.3) 32 (34.8) 1 (1.1) 92 (100)
Total 561 (53.3) 133 (12.6) 210 (19.9) 30 (2.9) 110 (10.5) 9 (0.9) 1,053 (100)
Numbers shown are n (percentage).
Figure 1. Cumulative proportion of colonoscopic surveillance out-
comes according to age. Individuals are censored at the first event.
The proportion of colonoscopies with an event is estimated by
smoothing and is forced to be non-decreasing in age by applying
the pool adjacent violators algorithm. – – – – – Adenoma or
worse, ———— Multiple Adenoma or worse, –  – –  high-rish
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interval cancers do occur during surveillance although they
may be detected at an early stage. There was no obvious dif-
ference in phenotype during colonoscopic surveillance
between FCC type X and LOFCC and these should be man-
aged as a single group.
Baseline colonoscopy results confirmed that FCC individu-
als have an increased prevalence of colonic neoplasia.11 The
median age at baseline colonoscopy was 47.5 years. At base-
line, 21.8% of individuals had one or more adenomas, includ-
ing 7.6% with high-risk adenomas, and 1.4% (n5 22)
asymptomatic cancers with a median age of 52 (range 34–
78).The (standardized prevalence) ratio for CRC was signifi-
cantly raised compared to the population of England.
We have analyzed the incidence of adenomas, high-risk
adenomas and multiple adenomas by age in Figure 1 (censor-
ing when an adenoma has been removed at colonoscopy). As
expected, there is an increasing incidence with age, and we
have shown that approximately 40% of individuals have at
least one adenoma, 20% multiple adenomas and 18% a high
risk adenoma by age 70 years. A similar trend is seen in
average risk individuals but with a much lower frequency.11,12
Cancers occurred more frequently in individuals with multi-
ple adenomas. Our definition of individuals with multiple
adenomas was introduced to avoid bias with varying duration
and frequency of colonoscopic surveillance. In individuals
classified as having multiple adenomas, the risk of an individ-
ual adenoma being high-risk was not increased although
there was an increased risk of an individual having a high-
risk adenoma. We were not able to demonstrate significant
clustering of multiple adenomas within families. Overall in
baseline and follow-up colonoscopies, adenomas were fairly
evenly distributed between the left and right colon (52% vs.
48% respectively).
During follow-up surveillance, the youngest age at which
a cancer was diagnosed was 42 and the eldest 77 with a
median age of 63 years. It is notable that five cancers
occurred within three years of a previous colonoscopy
although four of these cancers were detected at an early stage
(T1 or T2). In four of these cases, an adenoma was present
at the previous colonoscopy. There is a well-described miss
rate of significant pathology even with close colonoscopic
surveillance.12 In our analysis, we have assumed that pathol-
ogy detected on follow-up colonoscopy has developed since
the previous examination although, in fact, some of these
may represent neoplasia that was previously missed. Six of
the cancers were in the right side of the colon and three were
in the left colon. Lindor et al. report that in FCC type X ped-
igrees the cancers were predominantly left-sided.3 A higher
proportion of the interval cancers are right-sided than the
cancers diagnosed at baseline colonoscopy (67% vs. 26%
respectively, p5 0.017). There are reports that colonoscopic
surveillance in the general population is much less effective
at preventing right-sided than left-sided sided cancers and
this may also apply to FCC individuals.13 This result empha-
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right colon at colonoscopy, and that a repeat colonoscopy/
alternative procedure should be carried out if the examina-
tion is not complete with good views to the cecum.
Despite these nine cases, the incidence of CRC in this
study was very low at 1.14 per 1,000 person years. This com-
pares very favorably to 15.8 cancers per 1,000 person years in
individuals with LS undergoing surveillance previously
reported in the control arm of the CAPP2 study.14 There
may also be a role for aspirin chemoprevention in FCC
which has been demonstrated to have a protective effect in
randomized studies of individuals at population risk and also
in individuals with LS.14,15
It is possible that our cohort of patients included families
with LS, especially since several cancers were diagnosed
within 3 years of colonoscopy raising the possibility of an
accelerated adenoma–carcinoma pathway. LS was excluded
either by testing for loss of expression of MLH1 and MSH2
proteins using immunohistochemistry, the presence of DNA
MSI in one or more CRCs from an affected family member
and/or undertaking germline sequencing of two (MLH1 and
MSH2) or more DNA mismatch repair genes for alterations
(see Table 2). Mutations in MLH1 and MSH2 are responsi-
ble for the majority of cases of LS but mutation detection
techniques are imperfect. Approximately, 6% of cases of LS
are due to MSH6 mutations and 2% to PMS2 mutations.
Immunohistochemistry and/or germline sequencing for
MSH6 and PMS2 was not undertaken in all families. We
have reviewed in detail the genetic testing that had been
undertaken in the nine cancers that were diagnosed in the
cohort during surveillance (Table 7). In five cases, tumors
from several family members had been tested for DNA MSI
and germline sequencing also undertaken. We have also
looked at the incidence of extra-colonic cancers associated
with LS in our families and found no increase. This suggests
that our findings of advanced neoplasia on colonoscopic
surveillance are not due to undetected LS families being
included in the cohort.
This pooled analysis confirms that individuals from fami-
lies in which there is a dominant pattern of CRC inheritance,
but no evidence of DNA mismatch repair deficiency, are at
high risk of subsequently developing adenomas and CRC.
This is likely to be a genetically heterogeneous group. One
interesting finding from this study is that there was no
obvious difference in the colonoscopic findings of individuals
from FCC type X or LOFCC families and for this reason, we
have grouped them together. It is likely that they both repre-
sent a similar spectrum of genetic predispositions. Genome-
wide linkage studies have been undertaken in families with a
multiple adenoma phenotype and have demonstrated linkage
to various loci including 3q 21–24 and q21.1–26.2 and 9q22–
33,16–18 and a small proportion of cases may be due to atte-
nuated alterations of the APC gene. However, germline muta-
tions responsible for FCC have, by and large, not been
identified. Whole genome sequencing is now being used to
investigate individuals with multiple adenomas and may well
reveal novel genetic alterations predisposing to this pheno-
type.19 FCC may be due to a complex genetic model of dom-
inant genes, rare variants and low penetrance variants.
One of the strengths of this study is that each center has
a slightly different surveillance protocol (see Table 1). There
is variation in the age at which colonoscopic surveillance is
started, the intervals between examinations and whether
examinations are carried out in local hospitals or tertiary
referral centers. This reflects the breadth of clinical practice
in Europe and therefore provides a robust picture of the
effectiveness of colonoscopic surveillance in this high-risk
group. The number of prevalent cancer cases in this study is
compared to CRC cases in the general population in Eng-
land9 (rather than each country’s data) which is a weakness
of the study. The incidence in England is very similar to
other European countries included in this analysis although
slightly lower than Sweden and The Netherlands.20 However,
the higher incidence in these countries is not sufficient to
explain the high prevalence of CRC cases compared to the
general population of England.
Although multiple adenomas did subsequently develop in
individuals with a normal baseline colonoscopy, interval can-
cers predominantly occurred in individuals who had already
developed multiple adenomas. The incidence of adenomas
and cancers increases with age. As might be anticipated if
there is an autosomal dominant predisposition, 40% of at-
risk individuals never developed any type of polyp. These
results support the idea that colonoscopic surveillance might
be undertaken less frequently at a younger age and in those
that have not developed adenomas, whereas those who have
developed high-risk or multiple adenomas should undergo
more frequent colonoscopic surveillance (as is the current
practice).
In conclusion, there is no obvious difference in the out-
come of colonoscopic surveillance between FCC type X, in
which a family member had developed CRC before the age
of 50 years, and LOFCC, in which there were no cases of
CRC under the age of 50 years. In FCC there is a signifi-
cantly increased prevalence of CRC and a significantly
increased incidence of adenomas and advanced adenomas on
prospective colonoscopic surveillance compared to published
studies of average risk individuals of similar age. However,
there is a much lower incidence of interval cancers than seen
on colonoscopic surveillance in the CAPP2 study of LS.14
The frequency of adenomas increases with age and uncom-
mon interval cancers occur predominantly at a later age and
in individuals who have developed multiple adenomas. How-
ever, we estimate a high cumulative proportion of individuals
with a high-risk adenoma at age 40 of approximately 10%.
We suggest that colonoscopic surveillance with five yearly
intervals should commence between 30 and 40 years of age
although there is little evidence to suggest screening before
this age. Colonoscopic frequency should be increased if
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